An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101

This is an open-label long-term safety and efficacy study of orally administered SAT-3247 in patients with DMD including those who previously participated in SAT-3247-CL-101. The study will assess the long-term safety, tolerability and potential efficacy of long-term dosing of orally administered SAT-3247 60 mg in a 5-days on/2-days off (i.e. weekday dosing) regimen in an open-label design through 11 months (Group A) or 12 months (Group B), respectively. The study will enroll up to 30 participants, including up to 5 who previously participated in the SAT-3247-CL-101 study.